ArticleJournal of experimental & clinical cancer research : CR2025
Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.
Lorenzo Castagnoli et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.